The Pantsir-S1 is devastating against small, fast, or low-flying threats—of the kind that U.S.-built drones and JDAMs pose.

SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC ...

SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which ...

The 2-week-old Tula-Tu will make her public debut starting Friday, after veterinarians and care staff gave the green light. “We know everyone has been eager to see Tula, and we appreciate your ...

PORTLAND, Ore. (KOIN) — The baby elephant sensation Tula-Tu made her public debut on Friday when she joined the rest of the elephant herd at the Oregon Zoo, including being with her mother ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing deal worth up to $1.3 billion. AstraZeneca is buying out its roxadustat ...

Tula-Tu, a two-week-old female Asian elephant calf born at the Oregon Zoo, will finally make her public debut Friday. The baby elephant has spent the past few weeks bonding with her mother, Rose ...

Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new ...

Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought ...

The Oregon Zoo is set to welcome visitors to meet its newest resident, Tula-Tu, a 2-week-old Asian elephant calf. Beginning Friday, Feb. 21, Tula-Tu and her mother, Rose-Tu, will be available for ...

Danish pharma major Novo Nordisk (NOV: N) has sued KBP Biosciences and its founder and executive chairman, Huang Zhenhua, for $830 million in an application to the Singapore International Commercial ...

The Danish pharma giant plans to seek $830 million in damages from Singapore-based KBP Biosciences and KBP’s founder and executive chairman, Zhenhua Huang, Ph.D., according to a Feb. 14 ruling ...